Barrington analyst Michael Petusky lowered the firm’s price target on Dentsply Sirona (XRAY) to $14 from $18 and keeps an Outperform rating on the shares. While stating that Dentsply Sirona has “turned into the ultimate ‘prove it” story,” the firm believes the current valuation reflects “maximum skepticism” and argues that the risk/reward continues to favor investors with patience.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XRAY:
- Dentsply Sirona price target lowered to $12 from $14 at Morgan Stanley
- Dentsply Sirona price target lowered to $13 from $16 at Mizuho
- Dentsply Sirona price target lowered to $12 from $14 at JPMorgan
- Dentsply Sirona price target lowered to $14 from $18 at Baird
- Dentsply Sirona price target lowered to $13 from $16 at Piper Sandler